12． Schrier RW, Gross P, Gheorghiade M, Berl T,
Verbalis JG, Czerwiec FS, et al. : SALT Investigators.
１．
Planas R, Montoliu S, Ballesté B, et al. : Natural
Tolvaptan, a selective oral vasopressin V2-receptor
history of patients hospitalized formanagement of
antagonist, for hyponatremia. N Engl J Med. 2006; 355:
cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4:
1385-1394
２．
Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida
2099-2112
13． Pérez-Ayuso RM, Arroyo V, Planas R: Randomizedcomparative study of efficacy of furosemide
I, et al. : Evidence-based clinical practice guidelines for
versus spironolactone in nonazotemic cirrhosis with
liver cirrhosis 2015. J Gastroenterol. 2016; 51: 629-650
ascites. Relationship between the diuretic response
３．
Sakaida I, Terai S, Nakajima K, Shibasaki Y,
and the activity of the renin-aldosterone system.
Tachikawa S, Tsubouchi H: Predictive factors of the
pharmacological action of tolvaptan in patients with
liver cirrhosis: a post hoc analysis. J Gastroenterol.
Gastroenterology 1983; 84: 961-968
14．
Angeli P, Fasolato S, Mazza E: Combined versus
sequential diuretic treatment of ascites in non-
2017; 52: 229-236
azotaemic patients with cirrhosis: results of an open
４．
Chishina H, Hagiwara S, Nishida N, Ueshima K,
Sakurai T, Ida H, et al. : Clinical Factors Predicting the
Effect of Tolvaptan for Refractory Ascites in Patients
randomised clinical trial. Gut 2010; 59: 98-104
15． Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang
－73－
Okumoto，Saito，Nishina，Mizuno，Katsumi，Hoshikawa，Haga，Ueno
J, Guevara M, et al. : Tolvaptan, an oral vasopressin
A, Ohira H: Association between the Serum Sodium
antagonist, in the treatment of hyponatremia in
Levels and the Response to Tolvaptan in Liver
cirrhosis. J Hepatol. 2012; 56: 571-578
Cirrhosis Patients with Ascites and Hyponatremia.
16． Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M,
Tokoro S, et al. : Close correlation between urinary
Intern Med. 2018; 57: 2451-2458
21．
Boyer TD: Tolvaptan and hyponatremia in a patient
sodium excretion and response to tolvaptan in liver
cirrhosis patients with ascites. Hepatol Res. 2017; 47:
with cirrhosis. Hepatology. 2010; 51: 699-702
22．
Yamada T, Ohki T, Hayata Y, Karasawa Y,
E14-E21
Kawamura S, Ito D, et al. : Potential Effectiveness
17．
Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y,
of Tolvaptan to Improve Ascites Unresponsive to
Kodama K, Taniai M, et al. : Safety and efficacy of
Standard Diuretics and Overall Survival in Patients
long-term tolvaptan therapy for decompensated liver
with Decompensated Liver Cirrhosis. Clin Drug
cirrhosis. Hepatol Res. 2016; 46: E194-200
Investig. 2016; 36: 829-835
18． Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y,
23．
Wang S, Zhang X, Han T, Xie W, Li Y, Ma H,
Kodama K, Taniai M, et al. : The Outcome of Cirrhotic
et al. : Tolvaptan treatment improves survival of
Patients with Ascites Is Improved by the Normalization
cirrhotic patients with ascites and hyponatremia. BMC
of the Serum Sodium Level by Tolvaptan. Intern Med.
2017; 56: 2993-3001
Gastroenterol. 2018; 18: 137
24．
Okita K, Kawazoe S, Hasebe C, Kajimura K, Kaneko
19． Gaglio P, Marfo K, Chiodo J 3rd. Hyponatremia in
A, Okada M, et al. : ASCITES Dose-Finding Trial
cirrhosis and end-stage liver disease: treatment with
Group. Dose-finding trial of tolvaptan in liver cirrhosis
the vasopressin V₂-receptor antagonist tolvaptan. Dig
patients with hepatic edema: A randomized, double-
Dis Sci. 2012; 57: 2774-2785
blind, placebo-controlled trial. Hepatol Res. 2014; 44: 83-
20．
Hayashi M, Abe K, Fujita M, Okai K, Takahashi
－74－
91
...
論文の公開元へ
